Efficacy comparison of Recombinant Bovine Basic Fibroblast Growth Factor Eye Drops and Hydroxycarboside Eye Drops in the treatment of dry eye after age-related cataract operation
FANG Cheng CHEN Ling YIN Jin
Ophthalmology Department, Tongling People′s Hospital, Anhui Province, Tongling 244000, China
Abstract:Objective To compare the efficacy of Recombinant Bovine Basic Fibroblast Growth Factor (rb-bFGF) Eye Drops and Hydroxycarboside Eye Drops in the treatment of dry eye after age-related cataract (ARC) operation. Methods Eighty-nine patients with ARC who underwent phacoemulsification in Tongling People′s Hospital from January 2015 to June 2018 were observed. Patients were divided into observation group (45 cases) and control group (44 cases) by random number table method. On the basis of routine medication, the control group was treated with Hydroxycarboside Eye Drops after operation, while the observation group was treated with rb-bFGF Eye Drops after operation. After 3 months, the efficacy, inflammatory factor, clinical indicators and adverse reactions of the two groups were compared. Results The total effective rate of the observation group was higher than that of the control group (P < 0.05). After treatment, the levels of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in the two groups were significantly lower than those before treatment, and the observation group was significantly lower than the control group, the differences were statistically significant (P < 0.05). The Schirmer I test (SIt), fluorescein corneal staining (FL) and dry eye symptom score of the two groups were significantly lower than those before treatment, and the observation group was lower than the control group, the differences were statistically significant (P < 0.05). The tear break-up time (BUT) of the two groups after treatment was longer than that before treatment, and the observation group was longer than the control group, the differences were statistically significant (P < 0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P < 0.05). Conclusion rb-bFGF Eye Drops has better efficacy and safety in the treatment of dry eye after ARC operation, and can effectively improve inflammation, tear film injury and corneal condition. It is worthy of promotion in clinic.